Abstract:Objective Glucocorticoid (GC) excess decreases bone mineralization and microarchitecture and lead to reduced bone strength. Both anabolic agent parathroid hormone (PTH) and anti-resorptive agent alendronate (ALN) are used to prevent and treat GC-induced bone loss, yet these bone active agents alter bone turnover by very different mechanisms. Our study was to determine how PTH and ALN alter bone quality following GC excess.Methods Nine-month-old SD male rats were treated with methylprednisolone (5 mg/kg·d) or placebo (CON). Other two groups of GC-treated rats had either PTH(80 μg/kg·d) or ALN(4 mg/kg·d) intervention. All the animals were killed after 3 months, and femur and tibia isolated for indicated detection. Bone quality and quantity measurements were measured by dual x-ray absorptiometry (DEXA) for the degree of bone mineralization, histomorphometry for bone microarchitecture, biochemistry for bone turnover. Osteoblasts isolated from newborn rats were cultured in vitro. Cells were treated with 1) CON: placebo; 2)GC: Dexamethasone 10-5mol/L; 3) ALN: Alendronate 10-7mol/L; 4)PTH: human recombinant parathyroid hormone 10-7mol/L; 5)GC+ALN: Dexamethasone 10-5mol/L+ALN 10-7mol/L; 6)GC+PTH: Dexamethasone 10-5mol/L+ PTH 10-7mol/L. Osteoblast proliferation and osteogenic activity were identified by MTT, alkaline phosphatase detection, calcium nodules were observed by Alizarin red staining, and real-time PCR were performed to monitor the expression of several key genes regulating bone formation and mineralization as FGF23 and SOST.Results Spine and Femur BMD was reduced after GC treatment, and it was restored to CON level with GC+ALN and GC+PTH at site of femur and spine separately (P<0.05). Compared to the CON, GC treatment decreased trabecular bone volume, bone formation rate, mineral apposition rate and serum BGP, but increased osteoclast surface and serum TRAP5b (P<0.05). GC+PTH increased and GC+ALN restored trabecular bone volume to the CON levels (P<0.05 compared to GC). GC+PTH increased bone formation rate and serum BGP compared to GC (P<0.05), while GC+ALN increased mineral apposition rate (P<0.01) and reduced osteoclast surface and serum TRAP5b compared to GC (P<0.05). As to osteoblasts experiments, GC treatment decrease MTT and AKP activity, reduced calcium nodules significantly (P<0.05 compared to CON), however, GC+PTH and GC+ALN promoted osteoblast MTT and AKP to the CON levels, but PTH significantly inhibited the calcium nodules, whereas ALN increased it. Realtime-PCR revealed that SOST and FGF23 were up-regulated by GC treatment (P<0.05 compared to CON), but SOST gene was down-regulated after GC+PTH treatment (P<0.01 compared to GC), while SOST and FGF23 genes were both down-regulated by GC+ALN treatment (P<0.05 compared to GC). Conclusion GC excess increased expression of gene that inhibit osteoblast activity and gene that inhibit mineralization and which were associated with reduced bone formation and bone volume. The addition of both PTH and ALN improved bone mass and bone strength during concurrent GC treatment, with PTH lowering expression of SOST and increasing bone formation; while ALN lowered the expression of SOST and FGF23 and reversed the deterioration of bone mineralization induced by GC excess.

Protein kinase G2 activation restores Wnt signaling and bone mass in glucocorticoid-induced osteoporosis in mice

Glucocorticoid Signaling and Bone Biology

GAG and Collagen II Attenuate Glucocorticoid-Induced Osteoporosis by Regulating NF-κB and MAPK Signaling.

Targeting osteoblastic casein kinase-2 interacting protein-1 to enhance Smad-dependent BMP signaling and reverse bone formation reduction in glucocorticoid-induced osteoporosis

Curculigoside Regulates Proliferation, Differentiation, and Pro-Inflammatory Cytokines Levels in Dexamethasone-Induced Rat Calvarial Osteoblasts.

Dexamethasone suppresses osteogenesis of osteoblast via the PI3K/Akt signaling pathway in vitro and in vivo

Potential therapeutic targets of alendronate and PTH for glucocorticoid-induced bone loss

Galangin mitigates glucocorticoid-induced osteoporosis by activating autophagy of BMSCs via triggering the PKA/CREB signaling pathway

Vitamin K2 Can Rescue the Dexamethasone-Induced Downregulation of Osteoblast Autophagy and Mitophagy Thereby Restoring Osteoblast Function In Vitro and In Vivo

OP0187 Transgenic Disruption of Glucocorticoid-Signaling in Mature Osteoblasts and Osteocytes Attenuates Structural Bone Damage in a Long-Term Murine K/bxn Serum-Induced Arthritis Model

The osteocytic actions of glucocorticoids on bone mass, mechanical properties, or perilacunar remodeling outcomes are not rescued by PTH(1-34)

HIF-1α Regulates Glucocorticoid-Induced Osteoporosis Through PDK1/AKT/mTOR Signaling Pathway

Epimedin C Alleviates Glucocorticoid-Induced Suppression of Osteogenic Differentiation by Modulating PI3K/AKT/RUNX2 Signaling Pathway

Glucocorticoids Enhanced Osteoclast Autophagy Through the PI3K/Akt/mTOR Signaling Pathway

Protein kinase G1 regulates bone regeneration and rescues diabetic fracture healing

Excess glucocorticoids inhibit murine bone turnover via modulating the immunometabolism of the skeletal microenvironment

Glucocorticoids Activate the Local Renin–angiotensin System in Bone: Possible Mechanism for Glucocorticoid-Induced Osteoporosis

Combined Treatment with Cinnamaldehyde and PTH Enhances the Therapeutic Effect on Glucocorticoid-Induced Osteoporosis Through Inhibiting Osteoclastogenesis and Promoting Osteoblastogenesis.

Pharmic Activation of PKG2 Alleviates Diabetes-Induced Osteoblast Dysfunction by Suppressing PLCβ1-Ca2+-Mediated Endoplasmic Reticulum Stress.

Curcumin alleviates glucocorticoid-induced osteoporosis through the regulation of the Wnt signaling pathway

Haem Oxygenase-1 Induction Prevents Glucocorticoid-Induced Osteoblast Apoptosis Through Activation of Extracellular Signal–regulated Kinase1/2 Signalling Pathway